Gene · 2103
NIH grants1,602
NIH grants whose papers are about the gene, through NIH's grant-paper links.
121 to 140 of 1,602
Download this page as JSON| Grant | Title | ESRRB papers | Newest fiscal year |
|---|---|---|---|
| R01AA027456 | Transcriptional and non-transcriptional function of IRF3 in ALD | 1 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 1 | 2025 |
| R01AG048923 | Characterization of ApoE4 Induced Phospholipid Dysregulation in AD Pathogenesis | 1 | 2025 |
| R01AG080992 | Role of a novel risk loci HAVCR2 of late-onset Alzheimer's disease in the regulation of microglial response in neurodegeneration | 1 | 2025 |
| R01AI045050 | Characterization of SLE-susceptibility loci on mouse chromosome 1 | 1 | 2025 |
| R01AI049954 | Gene Transcription in SLE | 1 | 2025 |
| R01AI168005 | Staphylococcus aureus induced itch and neuro-immune signaling in skin infections | 1 | 2025 |
| R01AR043369 | MITF from control of pigmentation to melanoma risk | 1 | 2025 |
| R01AR072304 | Therapeutic strategies for treatment of giant congenital melanocytic nevi | 1 | 2025 |
| R01CA080728 | Oncogenic Impact of eIF4E-dependent RNA Export in Cancer | 1 | 2025 |
| R01CA098571 | Molecular Mechanisms of eIF4E Mediated Transformation | 1 | 2025 |
| R01CA113794 | The function of Snf5 (SMARCB1), an epigenetic tumor suppressor | 1 | 2025 |
| R01CA148761 | Therapeutic Targeting of Breast Cancer Tumor Initiating Cells | 1 | 2025 |
| R01CA172152 | Role of the SWI/SNF complex in tumor suppression | 1 | 2025 |
| R01CA187718 | Merkel cell polyomavirus infection, host response, and viral oncogenic mechanism | 1 | 2025 |
| R01CA194496 | Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands | 1 | 2025 |
| R01CA200653 | Interaction between the Epitranscriptome and Metabolism in L-2HG Driven Kidney Cancer | 1 | 2025 |
| R01CA204484 | Novel Enediyne-Based Antibody-Drug Conjugates for Cancers | 1 | 2025 |
| R01CA205406 | Leveraging Novel Randomized Clinical Trials of Vitamin D Supplementation in Patients with Colorectal Cancer: Impact on Survival and Anti-Tumor Immunity | 1 | 2025 |
| R01CA207209 | Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2103/grants?page=7